♦ Publications

Full Length Articles, Review Articles, and Chapters

  • Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin MD. Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus 2011;20:219-224.

 

  • Erkan D, Lockshin MD, on behalf of APS ACTION. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus 2012; 21:695-698

 

  • Levy R, Jesus GR. “APS ACTION no Brasil”. Brazilian Journal of Rheumatology 2012;52:811-814.

 

  • Erkan D, Pierangeli S, Lockshin MD. “Task Force Report on Antiphospholipid Syndrome Clinical Research.” In: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Eds: Erkan, Pierangeli. Springer, 2012; 247-257.

 

  • Andreoli L, Banzato A, Chighizola, CB, Pons-Estel GJ, Ramires de Jesus G, and Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infraction, and Deep Vein Thrombosis. Arthritis Care Res (Hoboken) 2013;65:1869-1873.

 

  • Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML on Behalf of APS ACTION. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74:2028-2033.

 

  • Chighizola C, Andreoli L, de Jesus GR, Banzato A, Pons-Estel G, Erkan D on Behalf of APS ACTION. The Association Between Antiphospholipid Antibodies and Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis. Lupus 2015;24:980-984.

 

  • Barbhaiya M, Andrade D, Erkan D; APS ACTION. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. Curr Rheumatol Rep. 2016;18:64

 

 

  • Barbhaiya M, Andrade D. Bertolaccini ML, Erkan D. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). In: Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights. Eds: Erkan D, Lockshin MD. Springer, 2017, p: 267.

 

  • Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG on Behalf of APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27:399-406.

 

 

 


Poster or Podium Presentations at Scientific Meetings

 

  • Andreoli L, Banzato A, Chighizola CB, Pons-Estel GJ, Ramires de Jesus G, Lockshin MD, Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis. Arthritis & Rheumatism 2012;64:S1035 (ACR 2012)

 

  • Chighizola CB, Ramires de Jesus G, Andreoli L, Banzato A, Pons-Estel GJ, Lockshin MD, Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity. Arthritis & Rheumatism 2012;64:S744 (ACR 2012)

 

  • Chighizola C, Andreoli L, Banzato A, de Jesus G, Pons-Estel G, Erkan D on Behalf of APS ACTION. The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature. Arthritis & Rheumatism 2013;65:S1129 (ACR 2013)

 

  • Vega J (Picture on the right), Erkan D on behalf of APS ACTION. Antiphosholipid Syndrome Alliance for Clinical Trials and International Networking. 14th International Congress on aPL Abstract Book 2013; P1-19:77 (14th International Congress on aPL 2013).

 

  • Erkan D, Andrade D, Tektonidou M, Fortin P, Ugarte A, Banzato A, Tincani A, Meroni PL, Cervera R, Levy R on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Initial Analysis. Arthritis & Rheumatism 2014;66:S1253-1254 (ACR 2014)

 

  • Zuily S, Wahl D, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for Identification of Different Clinical Phenotypes among Antiphospholipid Antibody-Positive Patients. Annals of Rheumatic Disease SAT0426 (EULAR 2015)

 

  • Bertolaccini ML, Willis R, Lakos G, Andrade D, Pengo V, Banzato A, Krilis S, Erkan D on behalf APS ACTION. APS ACTION Core Laboratory Validation Exercise: Comparison of Chemiluminescence immunoassay (CIA) and ELISA. Annals of Rheumatic Disease 2015: AB1071 (EULAR 2015)

 

  • Mackie IJ, Pengo V, Gray E, Andrade D, Krilis S, Willis R, Erkan D, Cohen H on behalf of APS ACTION. APS ACTION Core Laboratory Validation Exercise: An International Performance Assessment of Lupus Anticoagulant Tests Using Standardized Methods and Reagents. Journal of Thrombosis and Hemostasis 2015; 13(Suppl2):777 (ISTH2015)

 

  • Bertolaccini ML, Andrade D, Lakos G, Willis R, Pengo V, Banzato A, Cohen H, Krilis S, Erkan D on behalf of APS ACTION. APS ACTION Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA). Arthritis Rheumatol. 2015; 67 (suppl 10). #2190. (ACR 2015)

 

  • Ramires de Jesus G, Zuily S, Erkan D, Levy RA on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). #2198 (ACR 2015)

 

  • Zuily S, Chighizola CB, WAHL D, Meroni PL, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients [abstract]. Arthritis Rheumatol.2015; 67 (suppl 10).#2200 (ACR 2015)

 

  • Erkan D, Zuily S, Banzato A, De Ceulaer K, Cohen H, Tektonidou M, Andrade D on behalf of APS ACTION. APS ACTION Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk[abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10).#2189 (ACR 2015)

 

  • Zuily S, Andrade D, Erkan D, and Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Impact of SLE in the Clinical Phenotype of aPL-positive patients. Annals of Rheumatic Disease 2016;FRI0314 (EULAR 2016)

 

  • Sciascia S , Willis R , Pengo V, Krilis S , Andrande D, Erkan D, Bertolaccini M. on behalf of APS ACTION. APS ACTION Clinical Database & Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results. Lupus 2016;25 (Supp 1S):23 (15th International Congress on aPL 2016)

 

  • Efthymiou M , Mackie I , Lane P , Pengo V, Andrade D, Willis R, Krilis S , Erkan D, Cohen H on behalf of APS ACTION. APS ACTION Clinical Database & Repository Analysis: The Comparison of Real World and Core Laboratory Lupus Anticoagulant Results. Lupus 2016;25 (Supp 1S):23 (15th International Congress on aPL 2016)

 

  • Yazici A , Unlu O , Chighizola C , Erkan D, Petri M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Frequency & Significance of IgA Anticardiolipin and Antib2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with/without Lupus. Lupus 2016;25 (Supp 1S):27 (15th International Congress on aPL 2016)

 

  • Unlu O , Zuily S , Davis S, Andrade D , Erkan D, Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Impact of Systemic Lupus Erythematous on the Clinical Phenotype of Antiphospholipid Antibodypositive Patients. Lupus 2016;25 (Supp 1S):41 (15th International Congress on aPL 2016)

 

  • Sciascia S , Ramires de Jesu´s G , Zuily S , Levy R, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Utility of Global Antiphospholipid Syndrome Score (GAPSS) as a Tool to Assess Thrombosis Risk in Patients Presenting with Pure Obstetric APS. Lupus 2016;25 (Supp 1S):51 (15th International Congress on aPL 2016)

 

  • Zuily S, Clerc-Urmes I, Chighizola C , Baumann C, Wahl D, Meroni P, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for the Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients With a History of Pregnancy. Lupus 2016;25 (Supp 1S):61 (15th International Congress on aPL 2016)

 

  • Ramires de Jesus G , Sciascia S, Zuily S, Erkan D, Levy R on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Factors Associated with First Thrombosis in Patients Presenting with Pure Obstetric APS. Lupus 2016;25 (Supp 1S):61 (15th International Congress on aPL 2016)

 

  • Unlu O, Branch W, Fortin P, Gerosa M, Pons-Estel G, Tektonidou M, Ugarte A, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: First and Recurrent Thrombosis Risk After 720 Patient-Years of Follow-Up. Lupus2016;25 (Supp 1S):73 (15th International Congress on aPL 2016)

 

  • Zuily S, Clerc-Urmes I, Wahl, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Patients. Lupus 2016;25 (Supp1S):74 (15th International Congress on aPL 2016)

 

  • Zuily S, Clerc-Urmes I, Baumann C, Erkan D, Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis for the Associations Among ‘‘Non-Criteria’’ Antiphospholipid Antibody Manifestations. Lupus 2016;25 (Supp 1S):75 (15th International Congress on aPL 2016)

 

  • Unlu O, Erkan D, Tektonidou M and on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients. Lupus 2016;25 (Supp 1S):75 (15th International Congress on aPL 2016)

 

  • Ugolini-Lopes M, Rosa R, Nascimento I, R de Jesus G, Levy R, Erkan D, Andrade D onBehalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Primary Antiphospholipid Syndrome in Brazil versus Other Regions of the World. Lupus 2016;25 (Supp 1S):76 (15th International Congress on aPL 2016)

 

  • Erkan D, Sciascia S, Unlu O, Belmont M, Branch W, Cuadrado M, Gonzalez E, Knight J, Uthman I, Willis R, Zhang Z, Zuily S, Wahl D, Tektonidou M and on Behalf of APS ACTION. A Multicenter Randomized Controlled Trial of Hydroxychloroquine in Primary Thrombosis Prophylaxis of Persistently Antiphospholipid Antibody-positive Patientswithout Systemic Autoimmune Diseases. Lupus 2016;25 (Supp 1S): 88 (15th International Congress on aPL 2016)

 

  • Rodriguez-Pinto I , Pons-Estel G , Andreoli L, Tincani A, Espinosa G, Cervera R , Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and RepositoryAnalysis: “Real Life” Hydroxychloroquine use in Primary Antiphospholipid Syndrome.Lupus 2016;25 (Supp 1S): 90 (15th International Congress on aPL 2016)

 

  • Unlu O, Cohen H, Cuadrado M, Fortin P, R de Jesus G, Gerosa M, Knight J, Pengo V, Clinical Database and Repository Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients. Lupus 2016;25 (Supp 1S): 93 (15th International Congress on aPL 2016)

 

  • Unlu O, Cohen H, Cuadrado MJ, Fortin PR, Ramires de Jesus G, Gerosa M, Knight JK, Pengo V, Petri M, Rodriguez-Almaraz E, Zuily S, Erkan D on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients. Arthritis Rheumatol 2016; 68 (suppl10) #1064 (ACR 2016)

 

  • Unlu O, Erkan D, Tektonidou M on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients. Arthritis Rheumatol. 2016; 68(suppl 10) #1072 (ACR 2016)

 

  • Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Erkan D, Bertolaccini ML on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results. Arthritis Rheumatol. 2016; 68 (suppl 10). #1073 (ACR 2016)

 

  • Yazici A, Unlu O, Chighizola CB, Erkan D, Petri M, on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10) #1964 (ACR 2016)

 

  • Unlu O, Branch WD, Fortin PR, Gerosa M, Pons-Estel GJ, Tektonidou M, Ugarte A, Erkan D Clinical Database and Repository Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up [abstract]. Arthritis Rheumatol. 2016; 68(suppl 10) #1965 (ACR 2016)

 

  • Jackson WG, Oromendia C, Unlu O, Erkan D, and De Sancho MT. Recurrent Thrombosis in Patients with Antiphospholipid Antibodies and Arterial Thrombosis Treated with Antiplatelets and/or Anticoagulant Therapy. (ASH 2017)

 

  • Efthymiou M, Mackie I, Lane P, Pengo V, Andrade D, Willis R, Krilis S, Erkan D, Cohen H on Behalf of APS ACTION. APS ACTION: Comparison of Real World and Core Laboratory Lupus Anticoagulant Results. Res Pract Thromb Haemost. 2017;1(Suppl. 1):1104. (ISTH 2017)